-
The University of Texas Health Science Center at San Antonio has received a five-year, $15.5 million grant to conduct the San Antonio Heart and Mind Study, an extension of the original San Antonio Heart study conducted between 1979 and 2006.
-
The subsidies are the result of a 3-year, $3.4 million grant from the Texas Health and Human Services Commission.
-
San Antonio researchers are getting the band back together, in a way. They’re reaching out to people who participated in a groundbreaking 1979 study on heart disease and diabetes in the Latino population to see if they’d like to enroll in a new study.
-
Excess belly fat in midlife is linked to genes that may increase a person’s risk of developing Alzheimer's disease later in life.
-
The program from UT Health San Antonio attempts to reach people across the state by utilizing virtual clinic visits, free trips to labs and pharmacies, and working outside of the traditional medical ecosystem.
-
The idea that there may be medicines already out there, safe and approved by the FDA and just waiting to be rediscovered is tantalizing for scientists, doctors, and patients.
-
75 percent of the UT Health study participants saw a significant reduction in symptoms after testing a compressed form of prolonged exposure therapy.
-
The drug, lecanemab, was proven to moderately slow the disease in early stages. It also comes with the potential for some serious side effects, such as brain bleeding and brain inflammation.
-
The cryo-EM enables researchers to create 3-D models of individual proteins from thousands of images. This betters their understanding of how to target them for drug treatments.
-
While there are still many questions about the ultimate efficacy of the drug, lecanemab, Dr. Arash Salardini said it could provide a path forward for new Alzheimer's treatments, like AZT was for HIV.